pranlukast政府对血管内皮生长因子水平的影响在哮喘病人。

文章的细节

引用

复制到剪贴板

金泽H, Yoshikawa T, Hirata K, Yoshikawa J

pranlukast政府对血管内皮生长因子水平的影响在哮喘病人。

胸部。2004年5月,125 (5):1700 - 5。

PubMed ID

15136379 (在PubMed

]

文摘

研究目的:我们曾发现血管内皮生长因子(VEGF)水平在哮喘患者诱导痰增加,其水平与气道阻塞的程度密切相关,微血管通透性。因此,本研究旨在考察pranlukast的影响,选择性白三烯受体拮抗剂,VEGF水平诱导痰从steroid-untreated或steroid-treated哮喘病人。设计:双盲,随机,安慰剂对照,交叉研究。背景:大学医院。参与者:23哮喘病人(steroid-untreated, 13个病人;steroid-treated, 10位病人)和10个健康对照组。干预措施:所有哮喘患者接受治疗4周pranlukast(225毫克),和痰诱导前后进行四周疗程。测量和结果:steroid-untreated哮喘病人,平均比例的嗜酸性粒细胞(% EOS)和平均诱导痰嗜酸性粒细胞阳离子蛋白(ECP)水平显著下降4周后pranlukast管理局(% EOS:之前,16.7% (SD, 7.1%);之后,12.3% (SD, 4.0%);p = 0.03; ECP levels: before, 774 ng/mL [SD, 258 ng/mL]; after, 564 ng/mL [SD, 204 ng/mL]; p = 0.034). Moreover, VEGF levels in the induced sputum and the airway vascular permeability index also were decreased after pranlukast administration (VEGF levels: before, 5,670 pg/mL [SD, 1,780 pg/mL]; after, 4,380 pg/mL [SD, 1,540 pg/mL]; p = 0.026; airway vascular permeability index: before, 0.032 [SD, 0.012]; after, 0.017 [SD, 0.006]; p = 0.01). In addition, the change in airway vascular permeability index from before to after pranlukast administration was significantly correlated with the change in VEGF levels (r = 0.782; p = 0.007). However, in steroid-treated asthmatic patients there was no significant difference in mean VEGF levels in induced sputum between placebo administration (before, 3,640 pg/mL [SD, 1,020 pg/mL]; after, 3,640 pg/mL [SD, 960 pg/mL] and pranlukast administration (before, 3,660 pg/mL [SD, 940 pg/mL]; after, 2,950 pg/mL [SD, 890 pg/mL]). CONCLUSIONS: Pranlukast administration decreased airway microvascular permeability through, at least in part, a decrease in airway VEGF levels in steroid-untreated asthmatic patients. However, it is likely that pranlukast administration added little efficacy to inhaled corticosteroid therapy for reduction in airway VEGF levels.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Pranlukast	嗜酸性粒细胞阳离子蛋白	蛋白质	人类	未知的	其他/未知	细节